Wegovy 7.2mg Explained: Eligibility, Effectiveness and Availability
In this guide
What is Wegovy 7.2mg?
Wegovy (semaglutide) follows a step-up dosing schedule, starting low and increasing every four weeks as your body adjusts. Until recently, the highest maintenance dose was 2.4mg once a week.
The MHRA approved a new 7.2mg maintenance dose on 12 January 2026 for adults with obesity who need extra support to keep losing weight. This dose is given as three separate 2.4mg injections taken one after another. On 14 April 2026, the MHRA also approved a single-dose 7.2mg pen, which will make this easier — though it's not yet available in UK pharmacies, so it's worth checking with our pharmacy team on current stock.
Nothing about the medicine itself has changed — it's still the same active ingredient, semaglutide, at the same dose.
The Wegovy dose escalation pathway
Doses increase roughly every 4 weeks under clinical supervision. The step up to 7.2mg requires a minimum of 4 weeks at the 2.4mg maintenance dose.
Who is Wegovy 7.2mg suitable for?
The 7.2mg dose isn't a starting point — it's for people already established on Wegovy who need a higher dose to keep progressing.
- Adults with obesity (BMI of 30 kg/m² or above)
- Patients who've reached and tolerated 2.4mg for at least 4 weeks
- People using Wegovy for weight management, under clinical supervision
- People who are overweight (BMI below 30 kg/m²) using Wegovy for weight management
- Patients taking Wegovy specifically to reduce cardiovascular risk
Any dose change should only happen under clinical supervision. Our Weldricks pharmacy team can assess whether it's appropriate based on your progress, tolerance, and health history.
How effective is the 7.2mg dose?
The 7.2mg dose was tested in the STEP UP trial: a 72-week study of 1,407 adults with a BMI of 30 or above, all receiving diet and lifestyle support alongside their assigned treatment.
STEP UP reported results two ways: a treatment policy analysis (the primary, regulatory-standard measure, covering outcomes regardless of how consistently people took treatment) and a trial product analysis (outcomes among people who took treatment exactly as intended). The table below leads with treatment policy, as the more representative real-world measure.
| Outcome at 72 weeks (treatment policy) | Wegovy 7.2mg | Wegovy 2.4mg | Placebo |
|---|---|---|---|
| Average weight loss | 18.7% | 15.6% | 3.9% |
| Achieved 5% or more weight loss | 93.2% | 92.5% | 35.7% |
| Achieved 25% or more weight loss | 33.2% | 16.7% | 0.0% |
Among patients who adhered fully to treatment (trial product analysis), average weight loss was higher across all arms: 20.7% on 7.2mg, 17.5% on 2.4mg, and 2.4% on placebo. Source: STEP UP trial, Wegovy 7.2mg SmPC (Electronic Medicines Compendium).
Side effects to be aware of
| Symptom | Wegovy 7.2mg | Placebo |
|---|---|---|
| Nausea | 38.9% | 12.6% |
| Diarrhoea | 24.2% | 11.6% |
| Vomiting | 22.1% | 5.7% |
| Constipation | 20.4% | 7.6% |
| Altered skin sensation (dysaesthesia) | 21.6% | 0.3% |
| Hair loss | 5.3% | 1.0% |
Despite more people experiencing symptoms at the higher dose, permanent discontinuation due to gastrointestinal events was actually slightly lower on 7.2mg (3.2%, STEP UP trial) than on 2.4mg (4.3%, phase 3a trials) — most people who experience side effects find them manageable enough to continue. Most side effects overall were mild to moderate.
How do you switch from 2.4mg to 7.2mg?
Never increase your own dose. If you think 7.2mg might be right for you, speak to our Weldricks pharmacy team — they can clinically assess whether the 7.2mg dose is appropriate for you.
Is Wegovy 7.2mg available on the NHS?
Not yet. Although the MHRA has approved the dose, NHS availability depends on a separate review by NICE (the National Institute for Health and Care Excellence), which typically takes six to nine months after MHRA approval. Until that's complete, Wegovy 7.2mg is only available privately. Our Weldricks pharmacy team can clinically assess and supply Wegovy 7.2mg through our Weight Management Service.
This article is for general information only and does not replace advice from a doctor or pharmacist. Always speak to a healthcare professional before starting, stopping, or changing any medication.
Have questions about Wegovy 7.2mg or whether it's right for you? Book a consultation with our pharmacy team.
Sources
- Wegovy 7.2mg Solution for Injection in Pre-Filled Pen — Summary of Product Characteristics, Electronic Medicines Compendium: medicines.org.uk/emc/product/102093/smpc
- Wegovy 2.4mg FlexTouch — Summary of Product Characteristics, Electronic Medicines Compendium: medicines.org.uk/emc/product/13803/smpc
- MHRA approval of the single-dose 7.2mg injection device, Novo Nordisk press release via PharmiWeb (14 April 2026): pharmiweb.com
- "'Triple-strength' Wegovy injection gets MHRA approval," Pharmacy Magazine: pharmacymagazine.co.uk
- Wegovy (semaglutide) EPAR Product Information, European Medicines Agency: ema.europa.eu
- STEP UP trial (NCT05646706), Once-weekly semaglutide 7.2mg in adults with obesity — The Lancet Diabetes & Endocrinology: thelancet.com
- "STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity" (treatment policy estimand results), HCPLive: hcplive.com
- "Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial" (trial product estimand results), HCPLive: hcplive.com
- "STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo," Applied Clinical Trials Online: appliedclinicaltrialsonline.com
NHS/NICE timelines are described generally based on standard NICE technology appraisal processes — check nice.org.uk for live appraisal status before publishing.
FAQs
Is Wegovy 7.2mg the same medicine as Wegovy 2.4mg?
Yes. It's the same active ingredient, semaglutide, at a higher weekly dose.
Can I go straight onto 7.2mg without trying 2.4mg first?
No. You need to have been on the 2.4mg maintenance dose for at least four weeks before your our pharmacists can consider stepping you up.
Is 7.2mg suitable if I'm overweight rather than living with obesity?
No — the 7.2mg dose is currently only approved for adults with a BMI of 30 kg/m² or above.
Published 1st July 2026 by
Allan Green
Registered Pharmacist & Head of E-commerce
Allan has been a Registered Pharmacist for 25+ years
He specializes in Ecommerce and Over the Counter medicines.
He is a Registered Pharmacist, who studied at University of Bradford.
He has been with Weldricks since 2006, starting as a branch manager before moving into area management and deputy superintendent roles.
His current responsibilities include web development, marketing, content, customer service and web operations teams.
